Noti microarrays: Novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 13352-13377

  Kashuba, Vladimir ^a,b   Dmitriev, Alexey A ^c   Krasnov, George S ^c   Pavlova, Tatiana ^a   Ignatjev, Ilya ^a   Gordiyuk, Vasily V ^b   Gerashchenko, Anna V ^b   Braga, Eleonora A ^d   Yenamandra, Surya P ^a   Lerman, Michael ^e   Senchenko, Vera N ^c   Zabarovsky, Eugene ^a,c,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^d STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^e Affina Biotechnologies   (United States)

^f LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Biomarkers; Early detection of ovarian cancer; Epigenetics; Noti microarrays; Ovarian cancer; Prognosis of ovarian cancer

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; FORKHEAD TRANSCRIPTION FACTOR; PLASMA PROTEIN; RETINOBLASTOMA BINDING PROTEIN; RIBOSOME PROTEIN; THYROID HORMONE RECEPTOR BETA; TUMOR MARKER; TUMOR PROTEIN; ZINC FINGER PROTEIN; GCGGCCGC-SPECIFIC TYPE II DEOXYRIBONUCLEASES; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; EARLY DIAGNOSIS; EPIGENETICS; FEMALE; FOXP1 GENE; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IQSEC1 GENE; LOC285205 GENE; MARKER GENE; METHYLATION; MICROARRAY ANALYSIS; MOLECULAR CLONING; NBEAL2 GENE; OVARY CANCER; OVARY TUMOR; RBPS3 GENE; RPL15 GENE; SENSITIVITY AND SPECIFICITY; THYROID HORMONE RECEPTOR BETA GENE; TUMOR GENE; ZIC4 GENE; CANCER STAGING; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEIC ACID HYBRIDIZATION; NUCLEOTIDE SEQUENCE; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS;

BASE SEQUENCE; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE DELETION; GENE FREQUENCY; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84870686670     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131013352     Document Type: Article

References (120)

1. Hunn, J.; Rodriguez, G.C. Ovarian cancer: Etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol. 2012, 55, 3-23.
2. Chen, H.; Hardy, T.M.; Tollefsbol, T.O. Epigenomics of ovarian cancer and its chemoprevention. Front. Genet. 2011, 2, 67.
3. Yarbro, J.W.; Page, D.L.; Fielding, L.P.; Partridge, E.E.; Murphy, G.P. American Joint Committee on Cancer prognostic factors consensus conference. Cancer 1999, 86, 2436-2446.
4. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
5. Landen, C.N., Jr.; Birrer, M.J.; Sood, A.K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 2008, 26, 995-1005.
6. Montavon, C.; Gloss, B.S.; Warton, K.; Barton, C.A.; Statham, A.L.; Scurry, J.P.; Tabor, B.; Nguyen, T.V.; Qu, W.; Samimi, G.; et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 2012, 124, 582-588.
7. Barton, C.A.; Hacker, N.F.; Clark, S.J.; O'Brien, P.M. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol. Oncol. 2008, 109, 129-139.
8. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428.
9. Ibanez de Caceres, I.; Battagli, C.; Esteller, M.; Herman, J.G.; Dulaimi, E.; Edelson, M.I.; Bergman, C.; Ehya, H.; Eisenberg, B.L.; Cairns, P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004, 64, 6476-6481.
10. Kagan, J.; Srivastava, S.; Barker, P.E.; Belinsky, S.A.; Cairns, P. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res. 2007, 67, 4545-4549.
11. Laird, P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3, 253-266.
12. Wei, S.H.; Chen, C.M.; Strathdee, G.; Harnsomburana, J.; Shyu, C.R.; Rahmatpanah, F.; Shi, H.; Ng, S.W.; Yan, P.S.; Nephew, K.P.; et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 2002, 8, 2246-2252.
13. Wei, S.H.; Balch, C.; Paik, H.H.; Kim, Y.S.; Baldwin, R.L.; Liyanarachchi, S.; Li, L.; Wang, Z.; Wan, J.C.; Davuluri, R.V.; et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 2006, 12, 2788-2794.
14. Zabarovsky, E.R.; Klein, G.; Winberg, G. Lambda SK Diphasmids: phage lambda vectors for genomic, jumping, linking and cDNA libraries. Gene 1993, 127, 1-14.
15. Zabarovsky, E.R.; Boldog, F.; Erlandsson, R.; Kashuba, V.I.; Allikmets, R.L.; Marcsek, Z.; Kisselev, L.L.; Stanbridge, E.; Klein, G.; Sumegi, J.; et al. New strategy for mapping the human genome based on a novel procedure for construction of jumping libraries. Genomics 1991, 11, 1030-1039.
16. Zabarovsky, E.R.; Boldog, F.; Thompson, T.; Scanlon, D.; Winberg, G.; Marcsek, Z.; Erlandsson, R.; Stanbridge, E.J.; Klein, G.; Sumegi, J. Construction of a human chromosome 3 specific NotI linking library using a novel cloning procedure. Nucleic Acids Res. 1990, 18, 6319-6324.
17. Allikmets, R.L.; Kashuba, V.I.; Pettersson, B.; Gizatullin, R.; Lebedeva, T.; Kholodnyuk, I.D.; Bannikov, V.M.; Petrov, N.; Zakharyev, V.M.; Winberg, G.; et al. NotI linking clones as a tool for joining physical and genetic maps of the human genome. Genomics 1994, 19, 303-309.
18. Wang, J.Y.; Zabarovsky, E.R.; Talmadge, C.; Berglund, P.; Chan, K.W.; Pokrovskaya, E.S.; Kashuba, V.I.; Zhen, D.K.; Boldog, F.; Zabarovskaya, V.I.; et al. Somatic cell hybrid panel and NotI linking clones for physical mapping of human chromosome 3. Genomics 1994, 20, 105-113.
19. Zabarovsky, E.R.; Allikmets, R.; Kholodnyuk, I.; Zabarovska, V.I.; Paulsson, N.; Bannikov, V.M.; Kashuba, V.I.; Dean, M.; Kisselev, L.L.; Klein, G. Construction of representative NotI linking libraries specific for the total human genome and for human chromosome 3. Genomics 1994, 20, 312-316.
20. Kutsenko, A.S.; Gizatullin, R.Z.; Al-Amin, A.N.; Wang, F.; Kvasha, S.M.; Podowski, R.M.; Matushkin, Y.G.; Gyanchandani, A.; Muravenko, O.V.; Levitsky, V.G.; et al. NotI flanking sequences: A tool for gene discovery and verification of the human genome. Nucleic Acids Res. 2002, 30, 3163-3170.
21. Zabarovsky, E.R.; Gizatullin, R.; Podowski, R.M.; Zabarovska, V.V.; Xie, L.; Muravenko, O.V.; Kozyrev, S.; Petrenko, L.; Skobeleva, N.; Li, J.; et al. NotI clones in the analysis of the human genome. Nucleic Acids Res. 2000, 28, 1635-1639.
22. Li, J.; Protopopov, A.; Wang, F.; Senchenko, V.; Petushkov, V.; Vorontsova, O.; Petrenko, L.; Zabarovska, V.; Muravenko, O.; Braga, E.; et al. NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc. Natl. Acad. Sci. USA 2002, 99, 10724-10729.
23. Lind, G.E.; Skotheim, R.I.; Fraga, M.F.; Abeler, V.M.; Esteller, M.; Lothe, R.A. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J. Pathol. 2006, 210, 441-449.
24. Singh, U.; Roswall, P.; Uhrbom, L.; Westermark, B. CGGBP1 regulates cell cycle in cancer cells. BMC Mol. Biol. 2011, 12, 28.
25. Cody, N.A.; Shen, Z.; Ripeau, J.S.; Provencher, D.M.; Mes-Masson, A.M.; Chevrette, M.; Tonin, P.N. Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol. Carcinog. 2009, 48, 1077-1092.
26. Dong, Y.; Mao-Ying, Q.L.; Chen, J.W.; Yang, C.J.; Wang, Y.Q.; Tan, Z.M. Involvement of EphB1 receptor/ephrinB1 ligand in bone cancer pain. Neurosci. Lett. 2011, 496, 163-167.
27. Liu, S.; Liu, W.T.; Liu, Y.P.; Dong, H.L.; Henkemeyer, M.; Xiong, L.Z.; Song, X.J. Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents. Cancer Res. 2011, 71, 4392-4402.
28. Kuang, S.Q.; Bai, H.; Fang, Z.H.; Lopez, G.; Yang, H.; Tong, W.; Wang, Z.Z.; Garcia-Manero, G. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 2010, 115, 2412-2419.
29. Sheng, Z.; Wang, J.; Dong, Y.; Ma, H.; Zhou, H.; Sugimura, H.; Lu, G.; Zhou, X. EphB1 is underexpressed in poorly differentiated colorectal cancers. Pathobiology 2008, 75, 274-280.
30. Wang, J.D.; Dong, Y.C.; Sheng, Z.; Ma, H.H.; Li, G.L.; Wang, X.L.; Lu, G.M.; Sugimura, H.; Jin, J.; Zhou, X.J. Loss of expression of EphB1 protein in gastric carcinoma associated with invasion and metastasis. Oncology 2007, 73, 238-245.
31. Berardi, A.C.; Marsilio, S.; Rofani, C.; Salvucci, O.; Altavista, P.; Perla, F.M.; Diomedi-Camassei, F.; Uccini, S.; Kokai, G.; Landuzzi, L.; et al. Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. Anticancer Res. 2008, 28, 763-769.
32. Huynh-Do, U.; Vindis, C.; Liu, H.; Cerretti, D.P.; McGrew, J.T.; Enriquez, M.; Chen, J.; Daniel, T.O. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J. Cell Sci. 2002, 115, 3073-3081.
33. Pejovic, T.; Pande, N.T.; Mori, M.; Mhawech-Fauceglia, P.; Harrington, C.; Mongoue-Tchokote, S.; Dim, D.; Andrews, C.; Beck, A.; Tarumi, Y.; et al. Expression profiling of the ovarian surface kinome reveals candidate genes for early neoplastic changes. Translational Oncology 2009, 2, 341-349.
34. Chen, Z.; Xiao, Y.; Zhang, J.; Li, J.; Liu, Y.; Zhao, Y.; Ma, C.; Luo, J.; Qiu, Y.; Huang, G.; Korteweg, C.; Gu, J. Transcription factors E2A, FOXO1 and FOXP1 regulate recombination activating gene expression in cancer cells. PLoS One 2011, 6, e20475.
35. Goatly, A.; Bacon, C.M.; Nakamura, S.; Ye, H.; Kim, I.; Brown, P.J.; Ruskone-Fourmestraux, A.; Cervera, P.; Streubel, B.; Banham, A.H.; Du, M.Q. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod. Pathol. 2008, 21, 902-911.
36. Streubel, B.; Vinatzer, U.; Lamprecht, A.; Raderer, M.; Chott, A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005, 19, 652-658.
37. Fenton, J.A.; Schuuring, E.; Barrans, S.L.; Banham, A.H.; Rollinson, S.J.; Morgan, G.J.; Jack, A.S.; van Krieken, J.H.; Kluin, P.M. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006, 45, 164-168.
38. Banham, A.H.; Beasley, N.; Campo, E.; Fernandez, P.L.; Fidler, C.; Gatter, K.; Jones, M.; Mason, D.Y.; Prime, J.E.; Trougouboff, P.; et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001, 61, 8820-8829.
39. Toma, M.I.; Grosser, M.; Herr, A.; Aust, D.E.; Meye, A.; Hoefling, C.; Fuessel, S.; Wuttig, D.; Wirth, M.P.; Baretton, G.B. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 2008, 10, 634-642.
40. Wlodarska, I.; Veyt, E.; de Paepe, P.; Vandenberghe, P.; Nooijen, P.; Theate, I.; Michaux, L.; Sagaert, X.; Marynen, P.; Hagemeijer, A.; de Wolf-Peeters, C. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005, 19, 1299-1305.
41. Giatromanolaki, A.; Koukourakis, M.I.; Sivridis, E.; Gatter, K.C.; Harris, A.L.; Banham, A.H. Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: Relationship with estrogen receptors and HIF-1alpha expression. Mod. Pathol. 2006, 19, 9-16.
42. Brown, P.J.; Ashe, S.L.; Leich, E.; Burek, C.; Barrans, S.; Fenton, J.A.; Jack, A.S.; Pulford, K.; Rosenwald, A.; Banham, A.H. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 2008, 111, 2816-2824.
43. Green, M.R.; Gandhi, M.K.; Courtney, M.J.; Marlton, P.; Griffiths, L. Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFκB activity in Follicular Lymphoma. Leuk. Res. 2009, 33, 1699-1702.
44. Taylor, B.S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B.S.; Arora, V.K.; Kaushik, P.; Cerami, E.; Reva, B.; et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18, 11-22.
45. Kim, Y.S.; Hwan, J.D.; Bae, S.; Bae, D.H.; Shick, W.A. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer 2010, 10, 576.
46. Winn, R.A.; van Scoyk, M.; Hammond, M.; Rodriguez, K.; Crossno, J.T., Jr.; Heasley, L.E.; Nemenoff, R.A. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2006, 281, 26943-26950.
47. Bren-Mattison, Y.; van Putten, V.; Chan, D.; Winn, R.; Geraci, M.W.; Nemenoff, R.A. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005, 24, 1412-1422.
48. Leung, W.K.; Bai, A.H.; Chan, V.Y.; Yu, J.; Chan, M.W.; To, K.F.; Wu, J.R.; Chan, K.K.; Fu, Y.G.; Chan, F.K.; Sung, J.J. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004, 53, 331-338.
49. Tennis, M.A.; Vanscoyk, M.M.; Wilson, L.A.; Kelley, N.; Winn, R.A. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PLoS One 2012, 7, e32921.
50. Yoshioka, S.; King, M.L.; Ran, S.; Okuda, H.; Maclean, J.A., 2nd; McAsey, M.E.; Sugino, N.; Brard, L.; Watabe, K.; Hayashi, K. WNT7A Regulates Tumor Growth and Progression in Ovarian Cancer through the WNT/beta-Catenin Pathway. Mol. Cancer Res. 2012, 10, 496-482.
51. Calvo, R.; West, J.; Franklin, W.; Erickson, P.; Bemis, L.; Li, E.; Helfrich, B.; Bunn, P.; Roche, J.; Brambilla, E.; et al. Altered HOX and WNT7A expression in human lung cancer. Proc. Natl. Acad. Sci. USA 2000, 97, 12776-12781.
52. Winn, R.A.; Marek, L.; Han, S.Y.; Rodriguez, K.; Rodriguez, N.; Hammond, M.; van Scoyk, M.; Acosta, H.; Mirus, J.; Barry, N.; et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J. Biol. Chem. 2005, 280, 19625-19634.
53. Li, S.; Chiang, T.C.; Davis, G.R.; Williams, R.M.; Wilson, V.P.; McLachlan, J.A. Decreased expression of Wnt7a mRNA is inversely associated with the expression of estrogen receptor-alpha in human uterine leiomyoma. J. Clin. Endocrinol. Metabol. 2001, 86, 454-457.
54. Fluge, O.; Bruland, O.; Akslen, L.A.; Lillehaug, J.R.; Varhaug, J.E. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 2006, 16, 161-175.
55. Merritt, M.A.; Parsons, P.G.; Newton, T.R.; Martyn, A.C.; Webb, P.M.; Green, A.C.; Papadimos, D.J.; Boyle, G.M. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer 2009, 9, 378.
56. Zhang, X.L.; Peng, C.J.; Peng, J.; Jiang, L.Y.; Ning, X.M.; Zheng, J.H. Prognostic role of Wnt7a expression in ovarian carcinoma patients. Neoplasma 2010, 57, 545-551.
57. Prado, S.M.D.; Villaamil, V.M.; Gallego, G.A.; Calvo, M.B.; Cedrun, J.L.L.; Soliva, S.S.; Ayerbes, M.V.; Campelo, R.G.; Aparicio, L.M.A. Expression of Wnt gene family and frizzled receptors in head and neck squamous cell carcinomas. Virchows. Arch. 2009, 455, 67-75.
58. Hsu, Y.A.; Lin, H.J.; Sheu, J.J.; Shieh, F.K.; Chen, S.Y.; Lai, C.H.; Tsai, F.J.; Wan, L.; Chen, B.H. A novel interaction between interferon-inducible protein p56 and ribosomal protein L15 in gastric cancer cells. DNA Cell Biol. 2011, 30, 671-679.
59. Gerashchenko, G.V.; Bogatyrova, O.O.; Rudenko, E.E.; Kondratov, A.G.; Gordiyuk, V.V.; Zgonnyk, Y.M.; Vozianov, O.F.; Pavlova, T.V.; Zabarovsky, E.R.; Rynditch, A.V.; et al. Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas. Exp. Oncol. 2010, 32, 71-75.
60. Lin, H.; Wang, Y.; Zhang, X.; Liu, B.; Zhang, W.; Cheng, J. Prognostic significance of kappaB-Ras1 expression in gliomas. Med. Oncol. 2011, 29, 1272-1279.
61. Wang, H.; Zhao, L.N.; Li, K.Z.; Ling, R.; Li, X.J.; Wang, L. Overexpression of ribosomal protein L15 is associated with cell proliferation in gastric cancer. BMC Cancer 2006, 6, 91.
62. Dang, C.; Gottschling, M.; Manning, K.; O'Currain, E.; Schneider, S.; Sterry, W.; Stockfleth, E.; Nindl, I. Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol. Rep. 2006, 16, 513-519.
63. Willett, R.T.; Greene, L.A. Gata2 is required for migration and differentiation of retinorecipient neurons in the superior colliculus. J. Neurosci. 2011, 31, 4444-4455.
64. Kashiwabara, Y.; Sasaki, S.; Matsushita, A.; Nagayama, K.; Ohba, K.; Iwaki, H.; Matsunaga, H.; Suzuki, S.; Misawa, H.; Ishizuka, K.; et al. Functions of PIT1 in GATA2-dependent transactivation of the thyrotropin beta promoter. J. Mol. Endocrinol. 2009, 42, 225-237.
65. Kandimalla, R.; van Tilborg, A.A.; Kompier, L.C.; Stumpel, D.J.; Stam, R.W.; Bangma, C.H.; Zwarthoff, E.C. Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic Markers. Eur. Urol. 2012, 61, 1245-1256.
66. Bodor, C.; Renneville, A.; Smith, M.; Charazac, A.; Iqbal, S.; Etancelin, P.; Cavenagh, J.; Barnett, M.J.; Kramarzova, K.; Krishnan, B.; et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica 2012, 97, 890-894.
67. Hahn, C.N.; Chong, C.E.; Carmichael, C.L.; Wilkins, E.J.; Brautigan, P.J.; Li, X.C.; Babic, M.; Lin, M.; Carmagnac, A.; Lee, Y.K.; et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 2011, 43, 1012-1017.
68. Acosta, D.; Suzuki, M.; Connolly, D.; Thompson, R.F.; Fazzari, M.J.; Greally, J.M.; Montagna, C. DNA methylation changes in murine breast adenocarcinomas allow the identification of candidate genes for human breast carcinogenesis. Mamm. Genome 2011, 22, 249-259.
69. Wang, Y.; He, X.; Ngeow, J.; Eng, C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum. Mol. Genet. 2012, 21, 569-576.
70. Jazdzewski, K.; Boguslawska, J.; Jendrzejewski, J.; Liyanarachchi, S.; Pachucki, J.; Wardyn, K.A.; Nauman, A.; de la Chapelle, A. Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J. Clin. Endocrinol. Metab. 2011, 96, E546-E553.
71. Master, A.; Wojcicka, A.; Piekielko-Witkowska, A.; Boguslawska, J.; Poplawski, P.; Tanski, Z.; Darras, V.M.; Williams, G.R.; Nauman, A. Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma. Biochim. Biophys. Acta 2010, 1802, 995-1005.
72. Ling, Y.; Xu, X.; Hao, J.; Ling, X.; Du, X.; Liu, X.; Zhao, X. Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet. Cytogenet. 2010, 196, 140-145.
73. Vasiljevic, N.; Wu, K.; Brentnall, A.R.; Kim, D.C.; Thorat, M.A.; Kudahetti, S.C.; Mao, X.; Xue, L.; Yu, Y.; Shaw, G.L.; et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis. Markers 2011, 30, 151-161.
74. Muller, I.; Urban, K.; Pantel, K.; Schwarzenbach, H. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia. Ann. N. Y. Acad. Sci. 2006, 1075, 222-229.
75. Schwarzenbach, H.; Chun, F.K.; Muller, I.; Seidel, C.; Urban, K.; Erbersdobler, A.; Huland, H.; Pantel, K.; Friedrich, M.G. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int. 2008, 102, 253-258.
76. Qiu, H.; Lotan, R.; Lippman, S.M.; Xu, X.C. Lack of correlation between expression of retinoic acid receptor-beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer. Genes Chromosomes Cancer 2000, 28, 196-202.
77. Mannion, C.; Park, W.S.; Man, Y.G.; Zhuang, Z.; Albores-Saavedra, J.; Tavassoli, F.A. Endocrine tumors of the cervix: Morphologic assessment, expression of human papillomavirus, and evaluation for loss of heterozygosity on 1p,3p, 11q, and 17p. Cancer 1998, 83, 1391-1400.
78. Rowley, H.; Jones, A.; Spandidos, D.; Field, J. Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch. Otolaryngol. Head Neck Surg. 1996, 122, 497-501.
79. Buchhagen, D.L. Frequent involvement of chromosome 3p alterations in lung carcinogenesis: allelotypes of 215 established cell lines at six chromosome 3p loci. J. Cell. Biochem. Suppl. 1996, 24, 198-209.
80. Guigon, C.J.; Kim, D.W.; Willingham, M.C.; Cheng, S.Y. Mutation of thyroid hormone receptor-beta in mice predisposes to the development of mammary tumors. Oncogene 2011, 30, 3381-3390.
81. Kashuba, V.I.; Li, J.; Wang, F.; Senchenko, V.N.; Protopopov, A.; Malyukova, A.; Kutsenko, A.S.; Kadyrova, E.; Zabarovska, V.I.; Muravenko, O.V.; et al. RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies. Proc. Natl. Acad. Sci. USA 2004, 101, 4906-4911.
82. Anedchenko, E.A.; Dmitriev, A.A.; Krasnov, G.S.; Kondrat'eva, T.T.; Kopantsev, E.P.; Vinogradova, T.V.; Zinov'eva, M.V.; Zborovskaia, I.B.; Polotskii, B.E.; Sakharova, O.V.; et al. Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer. Mol. Biol. (Mosk) 2008, 42, 965-976.
83. Anedchenko, E.A.; Kiseleva, N.P.; Dmitriev, A.A.; Kiselev, F.L.; Zabarovskii, E.R.; Senchenko, V.N. Tumor suppressor gene RBSP3 in cervical carcinoma: Copy number and transcriptional level. Mol. Biol. (Mosk) 2007, 41, 86-95.
84. Pavlova, T.V.; Kashuba, V.I.; Muravenko, O.V.; Yenamandra, S.P.; Ivanova, T.A.; Zabarovskaia, V.I.; Rakhmanaliev, E.R.; Petrenko, L.A.; Pronina, I.V.; Loginov, V.I.; et al. Technology of analysis of epigenetic and structural changes of epithelial tumors genome with NotI-microarrays by the example of human chromosome. Mol. Biol. (Mosk) 2009, 43, 339-347.
85. Senchenko, V.N.; Anedchenko, E.A.; Kondratieva, T.T.; Krasnov, G.S.; Dmitriev, A.A.; Zabarovska, V.I.; Pavlova, T.V.; Kashuba, V.I.; Lerman, M.I.; Zabarovsky, E.R. Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 2010, 10, 75.
86. Sinha, S.; Singh, R.K.; Alam, N.; Roy, A.; Roychoudhury, S.; Panda, C.K. Frequent alterations of hMLH1 and RBSP3/HYA22 at chromosomal 3p22.3 region in early and late-onset breast carcinoma: Clinical and prognostic significance. Cancer Sci. 2008, 99, 1984-1991.
87. Ghosh, A.; Ghosh, S.; Maiti, G.P.; Sabbir, M.G.; Zabarovsky, E.R.; Roy, A.; Roychoudhury, S.; Panda, C.K. Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: Clinical and prognostic significance. Cancer Sci. 2010, 101, 1511-1520.
88. Mitra, S.; Mazumder Indra, D.; Bhattacharya, N.; Singh, R.K.; Basu, P.S.; Mondal, R.K.; Roy, A.; Zabarovsky, E.R.; Roychoudhury, S.; Panda, C.K. RBSP3 is frequently altered in premalignant cervical lesions: Clinical and prognostic significance. Genes Chromosomes Cancer 2010, 49, 155-170.
89. Kashuba, V.I.; Pavlova, T.V.; Grigorieva, E.V.; Kutsenko, A.; Yenamandra, S.P.; Li, J.; Wang, F.; Protopopov, A.I.; Zabarovska, V.I.; Senchenko, V.; et al. High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer. PLoS One 2009, 4, e5231.
90. Zheng, Y.S.; Zhang, H.; Zhang, X.J.; Feng, D.D.; Luo, X.Q.; Zeng, C.W.; Lin, K.Y.; Zhou, H.; Qu, L.H.; Zhang, P.; et al. MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 2012, 31, 80-92.
91. Shoubridge, C.; Walikonis, R.S.; Gecz, J.; Harvey, R.J. Subtle functional defects in the Arf-specific guanine nucleotide exchange factor IQSEC2 cause non-syndromic X-linked intellectual disability. Small GTPases 2010, 1, 98-103.
92. Someya, A.; Moss, J.; Nagaoka, I. The guanine nucleotide exchange protein for ADP-ribosylation factor 6, ARF-GEP100/BRAG2, regulates phagocytosis of monocytic phagocytes in an ARF6-dependent process. J. Biol. Chem. 2010, 285, 30698-30707.
93. Morishige, M.; Hashimoto, S.; Ogawa, E.; Toda, Y.; Kotani, H.; Hirose, M.; Wei, S.; Hashimoto, A.; Yamada, A.; Yano, H.; et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat. Cell. Biol. 2008, 10, 85-92.
94. Sabe, H.; Hashimoto, S.; Morishige, M.; Ogawa, E.; Hashimoto, A.; Nam, J.M.; Miura, K.; Yano, H.; Onodera, Y. The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis. Traffic 2009, 10, 982-993.
95. Gunay-Aygun, M.; Falik-Zaccai, T.C.; Vilboux, T.; Zivony-Elboum, Y.; Gumruk, F.; Cetin, M.; Khayat, M.; Boerkoel, C.F.; Kfir, N.; Huang, Y.; et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat. Genet. 2011, 43, 732-734.
96. SABiosciences Gene Network Central Home Page. Available online: http://www.sabiosciences.com/genenetwork/genenetworkcentral.php (accessed on 20 June 2012).
97. Tohyama, J.; Kato, M.; Kawasaki, S.; Harada, N.; Kawara, H.; Matsui, T.; Akasaka, N.; Ohashi, T.; Kobayashi, Y.; Matsumoto, N. Dandy-Walker malformation associated with heterozygous ZIC1 and ZIC4 deletion: Report of a new patient. Am. J. Med. Genet. A 2011, 155A, 130-133.
98. Aruga, J.; Nozaki, Y.; Hatayama, M.; Odaka, Y.S.; Yokota, N. Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer 2010, 10, 79.
99. Pourebrahim, R.; Van Dam, K.; Bauters, M.; De Wever, I.; Sciot, R.; Cassiman, J.J.; Tejpar, S. ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations. FEBS Lett. 2007, 581, 5122-5126.
100. Bataller, L.; Wade, D.F.; Graus, F.; Stacey, H.D.; Rosenfeld, M.R.; Dalmau, J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62, 778-782.
101. Sabater, L.; Bataller, L.; Suarez-Calvet, M.; Saiz, A.; Dalmau, J.; Graus, F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J. Neuroimmunol. 2008, 201-202, 163-165.
102. GeneCards Home Page. Available online: http://genecards.org/ (accessed on 20 June 2012).
103. Dunwell, T.L.; Hesson, L.B.; Pavlova, T.; Zabarovska, V.; Kashuba, V.; Catchpoole, D.; Chiaramonte, R.; Brini, A.T.; Griffiths, M.; Maher, E.R.; et al. Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics 2009, 4, 185-193.
104. Haraldson, K.; Kashuba, V.I.; Dmitriev, A.A.; Senchenko, V.N.; Kudryavtseva, A.V.; Pavlova, T.V.; Braga, E.A.; Pronina, I.V.; Kondratov, A.G.; Rynditch, A.V.; et al. LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibits cell growth and replication. Biochimie 2012, 94, 1151-1157.
105. Law, E.W.; Cheung, A.K.; Kashuba, V.I.; Pavlova, T.V.; Zabarovsky, E.R.; Lung, H.L.; Cheng, Y.; Chua, D.; Lai-Wan Kwong, D.; Tsao, S.W.; et al. Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. Oncogene 2012, 31, 728-738.
106. Buys, S.S.; Partridge, E.; Greene, M.H.; Prorok, P.C.; Reding, D.; Riley, T.L.; Hartge, P.; Fagerstrom, R.M.; Ragard, L.R.; Chia, D.; et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 2005, 193, 1630-1639.
107. Balch, C.; Fang, F.; Matei, D.E.; Huang, T.H.; Nephew, K.P. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009, 150, 4003-4011.
108. Baylin, S.B.; Jones, P.A. A decade of exploring the cancer epigenome-Biological and translational implications. Nat. Rev. Cancer 2011, 11, 726-734.
109. Baylin, S.B.; Ohm, J.E. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 2006, 6, 107-116.
110. Widschwendter, M.; Jiang, G.; Woods, C.; Muller, H.M.; Fiegl, H.; Goebel, G.; Marth, C.; Muller-Holzner, E.; Zeimet, A.G.; Laird, P.W.; et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004, 64, 4472-4480.
111. Collins, Y.; Dicioccio, R.; Keitz, B.; Lele, S.; Odunsi, K. Methylation of death-associated protein kinase in ovarian carcinomas. Int. J. Gynecol. Cancer 2006, 16 (Suppl 1), 195-199.
112. Gifford, G.; Paul, J.; Vasey, P.A.; Kaye, S.B.; Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10, 4420-4426.
113. Liggett, T.E.; Melnikov, A.; Yi, Q.; Replogle, C.; Hu, W.; Rotmensch, J.; Kamat, A.; Sood, A.K.; Levenson, V. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol. Oncol. 2011, 120, 113-120.
114. Melnikov, A.; Scholtens, D.; Godwin, A.; Levenson, V. Differential methylation profile of ovarian cancer in tissues and plasma. J. Molecular Diagn. 2009, 11, 60-65.
115. Gloss, B.S.; Samimi, G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2012, doi:10.1016/j.canlet.2011.12.036.
116. Kashuba, V.I.; Gizatullin, R.Z.; Protopopov, A.I.; Li, J.; Vorobieva, N.V.; Fedorova, L.; Zabarovska, V.I.; Muravenko, O.V.; Kost-Alimova, M.; Domninsky, D.A.; et al. Analysis of NotI linking clones isolated from human chromosome 3 specific libraries. Gene 1999, 239, 259-271.
117. Dmitriev, A.A.; Kashuba, V.I.; Haraldson, K.; Senchenko, V.N.; Pavlova, T.V.; Kudryavtseva, A.V.; Anedchenko, E.A.; Krasnov, G.S.; Pronina, I.V.; Loginov, V.I.; et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 2012, 7, 502-513.
118. AnalystSoft BioStat home page. Available online: http://www.analystsoft.com/en/products/biostat/ (accessed on 27 November 2009).
119. Altman, D.G.; Bland, J.M. Diagnostic tests. 1: Sensitivity and specificity. BMJ 1994, 308, 1552.
120. Dreijerink, K.; Braga, E.; Kuzmin, I.; Geil, L.; Duh, F.M.; Angeloni, D.; Zbar, B.; Lerman, M.I.; Stanbridge, E.J.; Minna, J.D.; et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 7504-7509.